



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



AB-CHMINACA metabolite M1A

Item No. 16387

CAS Registry No.: 2130879-83-1

Formal Name: N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-hydroxycyclohexyl)methyl]-1H-indazole-3-carboxamide

MF: $C_{20}H_{28}N_4O_3$

FW: 372.5


Purity: $\geq 98\%$ (mixture of diastereomers)

UV/Vis.: $\lambda_{\max}$: 210, 303 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥ 5 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Description

AB-CHMINACA (Item No. 15434) is a synthetic cannabinoid (CB) that is an analog of AB-FUBINACA (Item No. 14039), a potent agonist of the central CB_1 receptor ($K_i = 0.9$ nM).^{1,2} AB-CHMINACA metabolite M1A is a metabolite produced from AB-CHMINACA that can be detected in the urine.³ The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.

References

1. Uchiyama, N., Matsuda, S., Wakana, D., *et al.* New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. *Forensic Toxicol.* **31**(1), 93-100 (2013).
2. Buchler, I.P., Hayes, M.J., Hedge, S.G., *et al.* Indazole derivatives. *Pfizer Inc.* **WO2009/106982A1** (2009).
3. Wurita, A., Hasegawa, K., Minakata, K., *et al.* Identification and quantification of metabolites of AB-CHMINACA in a urine specimen of an abuser. *Leg. Med. (Tokyo)* **19**, (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/30/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM